FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079867625> ?p ?o ?g. }

• W2079867625 endingPage "1116" @default.
• W2079867625 startingPage "1110" @default.
• W2079867625 abstract "Background:Tegafur/uracil (UFT) is suitable for metronomic chemotherapy because of its underlying antiangiogenesis mechanism. This study aimed to assess the efficacy of adding daily oral UFT to gefitinib treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.Methods:Taiwanese patients who had adenocarcinoma of the lung and failed previous chemotherapy were randomized into gefitinib 250 mg daily alone (G) or plus daily oral UFT (GU). From November 2005 to August 2009, 115 patients were enrolled.Results:There were 58 patients in the G arm and 57 in the GU arm. One-year progression-free survival (PFS) was 18% in the G arm and 36.7% in the GU arm (p = 0.03). Fifty-four patients had tissue samples available for tumor epidermal growth factor receptor (EGFR) sequence analysis: 16 classical mutations and 8 wild types in the G arm, and 20 classical mutations and 10 wild-types in the GU arm. The addition of UFT significantly improved PFS in patients with EGFR mutations (14.4 versus 7.6 months, p = 0.0061). Forty-three patients underwent tumor tissue microvessel density measurement, and a trend favoring the addition of UFT to gefitinib treatment was found in those with low microvessel density (median PFS: 11.8 versus 2.8 months, p = 0.0536). The median survival time was 18.3 months in the G arm and 23.6 months in the GU arm (p = 0.381).Conclusion:Gefitinib plus UFT treatment had better PFS than gefitinib alone treatment. Gefitinib is effective in patients with EGFR mutations, and the addition of UFT treatment produced better PFS in these patients with mutations. Tegafur/uracil (UFT) is suitable for metronomic chemotherapy because of its underlying antiangiogenesis mechanism. This study aimed to assess the efficacy of adding daily oral UFT to gefitinib treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Taiwanese patients who had adenocarcinoma of the lung and failed previous chemotherapy were randomized into gefitinib 250 mg daily alone (G) or plus daily oral UFT (GU). From November 2005 to August 2009, 115 patients were enrolled. There were 58 patients in the G arm and 57 in the GU arm. One-year progression-free survival (PFS) was 18% in the G arm and 36.7% in the GU arm (p = 0.03). Fifty-four patients had tissue samples available for tumor epidermal growth factor receptor (EGFR) sequence analysis: 16 classical mutations and 8 wild types in the G arm, and 20 classical mutations and 10 wild-types in the GU arm. The addition of UFT significantly improved PFS in patients with EGFR mutations (14.4 versus 7.6 months, p = 0.0061). Forty-three patients underwent tumor tissue microvessel density measurement, and a trend favoring the addition of UFT to gefitinib treatment was found in those with low microvessel density (median PFS: 11.8 versus 2.8 months, p = 0.0536). The median survival time was 18.3 months in the G arm and 23.6 months in the GU arm (p = 0.381). Gefitinib plus UFT treatment had better PFS than gefitinib alone treatment. Gefitinib is effective in patients with EGFR mutations, and the addition of UFT treatment produced better PFS in these patients with mutations." @default.
• W2079867625 created "2016-06-24" @default.
• W2079867625 creator A5000877957 @default.
• W2079867625 creator A5004663085 @default.
• W2079867625 creator A5005838733 @default.
• W2079867625 creator A5014314211 @default.
• W2079867625 creator A5017257090 @default.
• W2079867625 creator A5023215362 @default.
• W2079867625 creator A5023696543 @default.
• W2079867625 creator A5047727465 @default.
• W2079867625 creator A5049040142 @default.
• W2079867625 creator A5052670273 @default.
• W2079867625 creator A5076810872 @default.
• W2079867625 date "2011-06-01" @default.
• W2079867625 modified "2023-10-04" @default.
• W2079867625 title "A Phase II Randomized Trial of Gefitinib Alone or with Tegafur/Uracil Treatment in Patients with Pulmonary Adenocarcinoma Who had Failed Previous Chemotherapy" @default.
• W2079867625 cites W1976972366 @default.
• W2079867625 cites W1989146386 @default.
• W2079867625 cites W2004929503 @default.
• W2079867625 cites W2005366538 @default.
• W2079867625 cites W2043696829 @default.
• W2079867625 cites W2064147032 @default.
• W2079867625 cites W2073952121 @default.
• W2079867625 cites W2079415755 @default.
• W2079867625 cites W2087708562 @default.
• W2079867625 cites W2090458114 @default.
• W2079867625 cites W2090944837 @default.
• W2079867625 cites W2099237130 @default.
• W2079867625 cites W2100608628 @default.
• W2079867625 cites W2110835998 @default.
• W2079867625 cites W2120819664 @default.
• W2079867625 cites W2122553809 @default.
• W2079867625 cites W2127101185 @default.
• W2079867625 cites W2131891275 @default.
• W2079867625 cites W2138297714 @default.
• W2079867625 cites W2139248078 @default.
• W2079867625 cites W2143859186 @default.
• W2079867625 cites W2148174696 @default.
• W2079867625 cites W2152755651 @default.
• W2079867625 cites W2153477391 @default.
• W2079867625 cites W2161821474 @default.
• W2079867625 cites W2162724777 @default.
• W2079867625 cites W2166084034 @default.
• W2079867625 cites W2169965478 @default.
• W2079867625 cites W2590412032 @default.
• W2079867625 cites W310150161 @default.
• W2079867625 doi "https://doi.org/10.1097/jto.0b013e3182121c09" @default.
• W2079867625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21415778" @default.
• W2079867625 hasPublicationYear "2011" @default.
• W2079867625 type Work @default.
• W2079867625 sameAs 2079867625 @default.
• W2079867625 citedByCount "28" @default.
• W2079867625 countsByYear W20798676252012 @default.
• W2079867625 countsByYear W20798676252013 @default.
• W2079867625 countsByYear W20798676252014 @default.
• W2079867625 countsByYear W20798676252015 @default.
• W2079867625 countsByYear W20798676252016 @default.
• W2079867625 countsByYear W20798676252017 @default.
• W2079867625 countsByYear W20798676252018 @default.
• W2079867625 countsByYear W20798676252020 @default.
• W2079867625 countsByYear W20798676252023 @default.
• W2079867625 crossrefType "journal-article" @default.
• W2079867625 hasAuthorship W2079867625A5000877957 @default.
• W2079867625 hasAuthorship W2079867625A5004663085 @default.
• W2079867625 hasAuthorship W2079867625A5005838733 @default.
• W2079867625 hasAuthorship W2079867625A5014314211 @default.
• W2079867625 hasAuthorship W2079867625A5017257090 @default.
• W2079867625 hasAuthorship W2079867625A5023215362 @default.
• W2079867625 hasAuthorship W2079867625A5023696543 @default.
• W2079867625 hasAuthorship W2079867625A5047727465 @default.
• W2079867625 hasAuthorship W2079867625A5049040142 @default.
• W2079867625 hasAuthorship W2079867625A5052670273 @default.
• W2079867625 hasAuthorship W2079867625A5076810872 @default.
• W2079867625 hasBestOaLocation W20798676251 @default.
• W2079867625 hasConcept C121608353 @default.
• W2079867625 hasConcept C126322002 @default.
• W2079867625 hasConcept C143998085 @default.
• W2079867625 hasConcept C2776256026 @default.
• W2079867625 hasConcept C2776694085 @default.
• W2079867625 hasConcept C2777299880 @default.
• W2079867625 hasConcept C2779438470 @default.
• W2079867625 hasConcept C2780580887 @default.
• W2079867625 hasConcept C2781182431 @default.
• W2079867625 hasConcept C71924100 @default.
• W2079867625 hasConcept C90924648 @default.
• W2079867625 hasConceptScore W2079867625C121608353 @default.
• W2079867625 hasConceptScore W2079867625C126322002 @default.
• W2079867625 hasConceptScore W2079867625C143998085 @default.
• W2079867625 hasConceptScore W2079867625C2776256026 @default.
• W2079867625 hasConceptScore W2079867625C2776694085 @default.
• W2079867625 hasConceptScore W2079867625C2777299880 @default.
• W2079867625 hasConceptScore W2079867625C2779438470 @default.
• W2079867625 hasConceptScore W2079867625C2780580887 @default.
• W2079867625 hasConceptScore W2079867625C2781182431 @default.
• W2079867625 hasConceptScore W2079867625C71924100 @default.
• W2079867625 hasConceptScore W2079867625C90924648 @default.
• W2079867625 hasIssue "6" @default.
• W2079867625 hasLocation W20798676251 @default.

• next